<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089787</url>
  </required_header>
  <id_info>
    <org_study_id>H-19014479</org_study_id>
    <secondary_id>2019-000404-15</secondary_id>
    <nct_id>NCT04089787</nct_id>
  </id_info>
  <brief_title>Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia</brief_title>
  <acronym>CAP5</acronym>
  <official_title>Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Benfield</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CAP5 is an investigator-initiated multicentre non-inferiority randomized controlled trial
      which aims to assess the efficacy and safety of shortened antibiotic treatment duration of
      community-acquired pneumonia (CAP) in hospitalized adult patients based on clinical stability
      criteria.

      Five days after initiation of antimicrobial therapy for CAP, participants are randomized 1:1
      to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic
      treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and
      afebrile for at least 48 hours. The control group receives antibiotics for a duration of 7
      days or longer at the discretion of the treating physician.

      The primary outcome is 90-day readmission-free survival which will be tested with a
      non-inferiority margin of 6%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day readmission-free survival</measure>
    <time_frame>within 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment</measure>
    <time_frame>within 90 days</time_frame>
    <description>Days that the participant receives antibiotic treatment for pneumonia, adding intravenous and oral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>within 90 days</time_frame>
    <description>Days from the date of hospital admission for pneumonia to the date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic adverse events</measure>
    <time_frame>within 90 days</time_frame>
    <description>Number of participants with adverse events with possible relation to the antibiotic treatment of pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>within 90 days</time_frame>
    <description>Number of participants with serious adverse events according to International Council of Harmonisation-Good Clinical Practice (ICH-GCP) guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major complications</measure>
    <time_frame>within 90 days</time_frame>
    <description>Number of participants with major complications, including pleural effusion, pleural empyema, lung abscess, respiratory failure, severe sepsis, renal failure, use of non-invasive or invasive ventilation, need for vasopressors, and intensive care unit (ICU) admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antimicrobials after discharge</measure>
    <time_frame>within 90 days</time_frame>
    <description>Days of antibiotic treatment for any reason after hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-discharge follow-up visits</measure>
    <time_frame>within 90 days</time_frame>
    <description>Number of participants with medical visits after hospital discharge, including visits at the outpatient clinic and at the general practitioner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>days 30 and 90</time_frame>
    <description>Number of participants with readmissions for reasons related to or unrelated to pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>in-hospital, days 30 and 90</time_frame>
    <description>Number of deaths by any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shortened antibiotic treatment of 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotic treatment of 7 days or longer at the discretion of the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Shortened antibiotic treatment of 5 days</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Antibiotic treatment of 7 days or longer at the discretion of the treating physician</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with community-acquired pneumonia; defined as new pulmonary infiltrate on
             chest X-ray and at least one symptom compatible with pneumonia (cough, fever, dyspnoea
             and/or chest pain)

          -  Initiation of antibiotics within 8 hours of the time of the chest X-ray with an
             infiltrate

          -  Age ≥ 18 years

          -  Afebrile (temperature ≤ 37.8 °C) for 48 hours at randomization

          -  Clinically stable at randomization (systolic blood pressure ≥ 90 mm Hg, heart rate ≤
             100/min., respiratory rate ≤ 24/min., peripheral oxygen saturation ≥ 90%)

        Exclusion Criteria:

          -  Immunosuppression (HIV-positive, neutropenia, corticosteroid treatment (≥10 mg/day of
             prednisone or the equivalent for &gt;30 days), chemotherapy, immunosuppressive agents,
             immunosuppressed after solid organ transplantation, asplenia)

          -  Hospitalization during the previous 14 days

          -  Antibiotic treatment (&gt;2 days) within the past 30 days

          -  Uncommon cause requiring longer duration of antimicrobial therapy (Pseudomonas
             aeruginosa, Staphylococcus aureus, Mycobacterium spp., fungi)

          -  Extrapulmonary infection (e.g. endocarditis, meningitis, or abscess)

          -  Multilobar involvement

          -  Pleural empyema or lung abscess

          -  Pleural effusion requiring drainage tube

          -  Intensive care unit (ICU) admittance

          -  Pregnancy and breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simone Bastrup Israelsen, MD</last_name>
    <phone>+45 40335495</phone>
    <email>simone.elisabeth.bastrup.israelsen.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Benfield, MD DMSc</last_name>
    <email>thomas.lars.benfield@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Bastrup Israelsen, MD</last_name>
      <email>simone.elisabeth.bastrup.israelsen.02@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Silkeborg Hospital</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012 Jan;67(1):71-9. doi: 10.1136/thx.2009.129502. Epub 2010 Aug 20. Review.</citation>
    <PMID>20729232</PMID>
  </reference>
  <reference>
    <citation>Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, Persaud AK, Raghuram A, Fernandez F, Beavin L, Bosson R, Fernandez-Botran R, Cavallazzi R, Bordon J, Valdivieso C, Schulte J, Carrico RM; University of Louisville Pneumonia Study Group. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017 Nov 13;65(11):1806-1812. doi: 10.1093/cid/cix647.</citation>
    <PMID>29020164</PMID>
  </reference>
  <reference>
    <citation>Egelund GB, Jensen AV, Andersen SB, Petersen PT, Lindhardt BØ, von Plessen C, Rohde G, Ravn P. Penicillin treatment for patients with Community-Acquired Pneumonia in Denmark: a retrospective cohort study. BMC Pulm Med. 2017 Apr 20;17(1):66. doi: 10.1186/s12890-017-0404-8.</citation>
    <PMID>28427381</PMID>
  </reference>
  <reference>
    <citation>Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, Lobo JL, Tomás L, Camino J, Nuñez J, Capelastegui A. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016 Sep 1;176(9):1257-65. doi: 10.1001/jamainternmed.2016.3633.</citation>
    <PMID>27455166</PMID>
  </reference>
  <reference>
    <citation>Aliberti S, Ramirez J, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, Carugati M, Valenti V, Marchioni M, Camera M, Piro R, Del Forno M, Milani G, Faverio P, Richeldi L, Deotto M, Villani M, Voza A, Tobaldini E, Bernardi M, Bellone A, Bassetti M, Blasi F. Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulm Pharmacol Ther. 2017 Aug;45:191-201. doi: 10.1016/j.pupt.2017.06.008. Epub 2017 Jun 27.</citation>
    <PMID>28666965</PMID>
  </reference>
  <reference>
    <citation>Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003 Sep 15;37(6):752-60. Epub 2003 Aug 28. Erratum in: Clin Infect Dis. 2003 Oct 15;37(8):1147.</citation>
    <PMID>12955634</PMID>
  </reference>
  <reference>
    <citation>el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJ, Weenink C, Bossuyt PM, Speelman P, Opmeer BC, Prins JM. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006 Jun 10;332(7554):1355.</citation>
    <PMID>16763247</PMID>
  </reference>
  <reference>
    <citation>Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, Höffken G. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J. 2003 Jan;21(1):135-43.</citation>
    <PMID>12570122</PMID>
  </reference>
  <reference>
    <citation>File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007 Jul;60(1):112-20. Epub 2007 May 30.</citation>
    <PMID>17537866</PMID>
  </reference>
  <reference>
    <citation>Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017 Sep 1;177(9):1308-1315. doi: 10.1001/jamainternmed.2017.1938.</citation>
    <PMID>28604925</PMID>
  </reference>
  <reference>
    <citation>Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, Jarlier V, Voss A, Pittet D. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013 Nov 18;2:31. doi: 10.1186/2047-2994-2-31. eCollection 2013.</citation>
    <PMID>24237856</PMID>
  </reference>
  <reference>
    <citation>Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S97-100. doi: 10.1093/cid/ciu542.</citation>
    <PMID>25261548</PMID>
  </reference>
  <reference>
    <citation>Madaras-Kelly KJ, Burk M, Caplinger C, Bohan JG, Neuhauser MM, Goetz MB, Zhang R, Cunningham FE; Pneumonia Duration of Therapy Medication Utilization Evaluation Group. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation. J Hosp Med. 2016 Dec;11(12):832-839. doi: 10.1002/jhm.2648. Epub 2016 Aug 16. Review.</citation>
    <PMID>27527659</PMID>
  </reference>
  <reference>
    <citation>Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S, Ramirez JA. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2010 Jul;36(1):128-34. doi: 10.1183/09031936.00130909. Epub 2009 Nov 19.</citation>
    <PMID>19926738</PMID>
  </reference>
  <reference>
    <citation>Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007 Sep;120(9):783-90.</citation>
    <PMID>17765048</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. Drugs. 2008;68(13):1841-54.</citation>
    <PMID>18729535</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.</citation>
    <PMID>17278083</PMID>
  </reference>
  <reference>
    <citation>Schrag SJ, Peña C, Fernández J, Sánchez J, Gómez V, Pérez E, Feris JM, Besser RE. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001 Jul 4;286(1):49-56.</citation>
    <PMID>11434826</PMID>
  </reference>
  <reference>
    <citation>Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98.</citation>
    <PMID>14625336</PMID>
  </reference>
  <reference>
    <citation>File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis. 2004 Sep 1;39 Suppl 3:S159-64. Review.</citation>
    <PMID>15546111</PMID>
  </reference>
  <reference>
    <citation>Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, Bouvenot G, Eschwége E. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998 Feb 4;279(5):365-70.</citation>
    <PMID>9459469</PMID>
  </reference>
  <reference>
    <citation>Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998 May 13;279(18):1452-7.</citation>
    <PMID>9600479</PMID>
  </reference>
  <reference>
    <citation>Menéndez R, Torres A, Rodríguez de Castro F, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, Benítez Moya JM, Ruiz-Manzano J, Blanquer J, Pérez D, Puzo C, Sánchez-Gascón F, Gallardo J, Alvarez CJ, Molinos L; Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004 Dec 15;39(12):1783-90. Epub 2004 Nov 18.</citation>
    <PMID>15578400</PMID>
  </reference>
  <reference>
    <citation>Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill AT. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis. Clin Microbiol Infect. 2011 Dec;17(12):1852-8. doi: 10.1111/j.1469-0691.2011.03542.x. Epub 2011 Sep 15.</citation>
    <PMID>21919994</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Benfield</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Community-acquired pneumonia</keyword>
  <keyword>Treatment duration</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Pneumonia, Bacterial</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04089787/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

